Safety and Efficacy of Exenatide as Monotherapy

• Status: Completed
• Trial end date: 2007-09-01

Summary

This Phase 3 trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo with respect to glycemic control in drug-naive patients with type 2 diabetes treated with diet and exercise.

• Phase: Phase 3

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Eli Lilly and Company
• Treatments: Exenatide